Incyclix Bio

Incyclix Bio is a development-stage pharmaceutical company developing small molecule inhibitors of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers. The team’s unique insights about the biology and structure of CDKs will facilitate the rapid discovery and development of a novel, potent, and selective CDK2 inhibitor to treat patients whose tumors are insensitive to CDK4/6 inhibition.

The lead product candidate, AVB-500, is an ultra-high affinity decoy protein that starves the GAS6/AXL signaling pathway. AVB-500 is being evaluated in platinum resistant ovarian cancer (phase 3), renal cell cancer (phase 2), and pancreatic adenocarcinoma (phase 1b).

Aruna Bio is advancing a new class of cell-free biologics, exosomes, for the treatment of neurodegenerative disorders and leveraging a novel platform to optimize the delivery of RNAs, antibodies, genes and small molecules.

Liquidia Technologies (LQDA) is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. FDA has tentatively approved treprostinil inhalation powder for PAH.

Sapience Therapeutics is a clinical stage biotechnology company focused on developing its lead compound, ST101, which is a peptide inhibitor of C/EBPbeta. It has FDA Fast Track designation for advanced cutaneous melanoma and GBM. The pipeline is full of other compounds, including a beta-catenin antagonist.

Carbon3D, a Silicon Valley based company, was founded in 2013 in Chapel Hill, NC. Working at the intersection of hardware, software and molecular science, Carbon3D is delivering on the promise of 3D printing, allowing commercial customers to go beyond basic prototyping to achieve 3D manufacturing.

A spinout from Duke University, developing immunotherapies for autoimmunity, cancer and immunodeficiency.

Developing "on demand" pharmaceuticals to restore voluntary control of bladder and bowel for people with spinal cord injury and neurological conditions.

Cosela (an IV CDK4/6 inhibitor) is approved for prevention of chemotherapy myelosuppression in SCLC and is being studied for antitumor effects in several other tumor types.

An operating private equity fund that in-licenses drug candidates and develops through late-stage for ultimate sale to a commercializing company. Auven also has a large position in ADCT (NASDAQ).

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology. Phase 3 trials are underway in pediatric myopia, presbyopia and pharmacologic mydriasis.

Jumo professionals provide content supporting clinical trials, promoted brands, and a COVID-19 Resource Center.